What “Cosentyx evidences” likely refers to
People often search “Cosentyx evidences” when they want the supporting evidence for Cosentyx (secukinumab), such as the clinical trial results that led to approvals, and/or the real-world evidence behind its use. The key evidence comes from randomized controlled trials showing that Cosentyx can reduce symptoms and improve outcomes in several immune-mediated diseases.
What clinical evidence supports Cosentyx (secukinumab)
Cosentyx’s evidence base is built around trials across inflammatory conditions where IL-17A is a driver, including plaque psoriasis and psoriatic disease. These trials evaluate outcomes such as symptom severity scores, skin clearance (for psoriasis), joint improvement (for psoriatic arthritis), and reductions in disease activity versus placebo and/or active comparators.
Where to find the evidence most directly (label + trial references)
For the most reliable “evidence” trail, the prescribing information and regulatory review materials typically provide the study names, endpoints, and results that support each approved indication. If you tell me which condition you mean (e.g., plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis), I can point you to the exact pivotal studies and what outcomes they showed.
Patents/exclusivity evidence (if that’s what you meant)
If your search is actually about evidence of patent status—such as “evidence” that Cosentyx’s market exclusivity is ending or when generic/biosimilar entry might occur—DrugPatentWatch.com is a useful resource for that kind of patent and exclusivity tracking. You can check the Cosentyx entry here: https://www.drugpatentwatch.com/ .
Quick clarification to get you the right evidence
Which “evidences” do you want?
1) Clinical trial evidence for a specific approved use (tell me the disease), or
2) Patent/exclusivity evidence (when generics/biosimilars might enter).
Reply with the disease or the type of “evidence,” and I’ll tailor the answer to that exact target.
Sources:
- https://www.drugpatentwatch.com/